Aesica Appoints Chris Gowland as Chief Operating Officer
Aesica has appointed Chris Gowland as Chief Operating Officer, a new position created to further enhance the company's operational performance in APIs and formulated product manufacturing services.
Aesica, a global contract development and manufacturing organization (CDMO), announced that it has appointed Chris Gowland as Chief Operating Officer. This new position was created to further enhance the company’s operational performance in APIs and formulated product manufacturing services.
As COO, Gowland has overall responsibility for all operating strategy, which includes setting of operational standards and driving continuous improvement across the company’s manufacturing capabilities in API and formulated products.
He will also be responsible for the management of capital expenditure, procurement of materials and services, managing the supply chain, and overseeing capacity expansion across the group to ensure that Aesica meets full customer demand whilst delivering maximum service value.
Gowland is now in charge of the operational performance and general management of all Aesica manufacturing sites including Queenborough and Cramlington in the UK, Monheim and Zwickau in Germany, and Pianezza in Italy.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
